World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 February 2015
Main ID:  NCT00195546
Date of registration: 13/09/2005
Prospective Registration: No
Primary sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Public title: Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause
Scientific title: A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause
Date of first enrolment: April 2005
Target sample size: 465
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT00195546
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment  
Phase:  Phase 3
Countries of recruitment
Belgium Croatia Czech Republic Finland France Hungary Mexico Netherlands
Poland Romania South Africa Spain Sweden Ukraine United Kingdom
Contacts
Name:     Trial Manager
Address: 
Telephone:
Email:
Affiliation:  For Hungary, Croatia, WPBUMED@wyeth.com
Name:     Medical Monitor
Address: 
Telephone:
Email:
Affiliation:  Wyeth is now a wholly owned subsidiary of Pfizer
Name:     Trial Manager
Address: 
Telephone:
Email:
Affiliation:  For Poland, WVWZMED@wyeth.com
Name:     Trial Manager
Address: 
Telephone:
Email:
Affiliation:  For Finland, Sweden, MedInfoNord@wyeth.com
Name:     Trial Manager
Address: 
Telephone:
Email:
Affiliation:  For Ukraine, Romania, WPVIMED@wyeth.com
Name:     Trial Manager
Address: 
Telephone:
Email:
Affiliation:  For Belgium, trials-BEL@wyeth.com
Name:     Trial Manager
Address: 
Telephone:
Email:
Affiliation:  For Czech Republic, WPPGCLI@wyeth.com
Name:     Trial Manager
Address: 
Telephone:
Email:
Affiliation:  For Mexico, gomezlj@wyeth.com
Name:     Trial Manager
Address: 
Telephone:
Email:
Affiliation:  For Netherlands, trials-NL@wyeth.com
Key inclusion & exclusion criteria

Inclusion Criteria:

- Postmenopausal women of age 40 to 65 seeking treatment for hot flashes with last
natural menstrual period (LNMP) completed at least 12 months prior to screening.

- Minimum of 7 moderate to severe hot flashes per day or 50 per week recorded for 7
consecutive days

- Body Mass Index less than or equal to 34 kg/m2 using the nomograph for BMI.

Exclusion Criteria:

- History, presence, or suspicion of estrogen-dependent neoplasia; Malignancy, or
treatment for malignancy, within the previous 2 years.

- Active or recent arterial thromboembolic disease; History of venous thromboembolism

- History of cerebrovascular accident, stroke, or transient ischemic attack -

- Presence of major depressive disorder, bipolar disorder, psychotic disorder, or
generalized anxiety disorder requiring therapy

- Persistent elevated blood pressure



Age minimum: 40 Years
Age maximum: 65 Years
Gender: Female
Health Condition(s) or Problem(s) studied
Menopause
Intervention(s)
Drug: DVS-233
Primary Outcome(s)
To assess the efficacy and safety of DVS-233 SR compared with placebo for treatment of vasomotor symptoms (VMS) associated with menopause and to compare the bleeding incidence of DVS-233 SR and tibolone.
Secondary Outcome(s)
To assess the effects of DVS-233 SR and tibolone on changes from baseline in weight, breast pain, and health outcomes indicators.
Secondary ID(s)
3151A2-321
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history